GLOBUS MEDICAL Business Summary

Globus Medical Inc. (GMED) is a leading musculoskeletal technology company that generates revenue primarily through the sale of surgical implants, instruments, and enabling technologies to hospitals and surgical centers. The company’s business is divided into two primary segments: Musculoskeletal Solutions, which encompasses a comprehensive portfolio of spinal, orthopedic, and trauma products, and Enabling Technologies, which includes the Excelsius ecosystem for robotic navigation and surgical imaging. Following its landmark $3.1 billion merger with NuVasive in 2023 and the 2025 acquisition of Nevro, Globus has significantly expanded its footprint into spinal cord stimulation and neuromodulation. The company currently holds the position of the second-largest player in the global spine market with an estimated 16–23% market share, trailing only Medtronic while competing aggressively with industry titans such as DePuy Synthes (Johnson & Johnson), Stryker, and Zimmer Biomet. Globus Medical was founded in 2003 by David C. Paul, who currently serves as Executive Chairman and previously held leadership roles in product development at Synthes. The executive leadership team is led by President and CEO Keith Pfeil, who was appointed in July 2025 after serving as the company’s COO and CFO; Pfeil previously held executive roles at CSS Industries. Supporting him is CFO Kyle Kline, a former Deloitte audit leader who joined Globus in 2017 and was promoted to the top financial post in 2025. The company’s board of directors includes notable industry veterans such as Dr. John A. DeFord, the former Chief Technology Officer of Becton Dickinson. Major institutional backing is provided by prominent investors including Vanguard and Invesco, reflecting the company's transition from a venture-backed startup to a dominant S&P 500 musculoskeletal powerhouse.